#Stephen Bancel

[andronetalks]

Moderna CEO Bancel steps down as sales chief, Bloomberg News reports

Reuters By ReutersNovember 5, 202412:40 PM EST Nov 5 (Reuters) – Vaccine maker Moderna’s (MRNA.O), opens new tab chief executive officer Stephane Bancel will vacate his role as the company’s chief commercial officer, Bloomberg News reported on Tuesday citing one person familiar with the matter.The company’s president Stephen Hoge will take charge of sales as well as medical and research affairs,…

[xtruss]

‘Unprecedented Greed’: Sanders Slams Moderna After Company Confirms $130 Price for Covid Jab

After seemingly claiming earlier this year that it would drop plans to dramatically hike the price of its SARS-CoV-2 vaccine, Moderna said on Wednesday that the price of the shot would increase from $26 per dose to $130.

“We tried to think very reasonably about the price of this, and I think we’ve landed on a price that is consistent with value,” Moderna President Stephen Hoge told federal lawmakers at a Wednesday hearing of the Senate Health, Education, Labor and Pensions Committee.

He added that the price could change depending on circumstances, and that the company was open to financing programs for uninsured patients to afford the jab.

That hearing was called by committee chair US Sen. Bernie Sanders (I-VT), who denounced Moderna’s planned price hike as “an unprecedented level of corporate greed.”

“As soon as Moderna started to receive billions of dollars from the federal government, Mr. Bancel literally became a billionaire overnight and is now worth over $4 billion. He was also able to secure a golden parachute for himself worth another $926 million after he leaves the company. But let’s be clear: Mr. Bancel is not alone,” Sanders said at the hearing, referring to Moderna CEO Steve Bancel.

“None of these four individuals were billionaires before the taxpayers of our country funded the Covid-19 vaccine,” he said, adding that Moderna was “thanking the taxpayers of the US by proposing to quadruple the price of the Covid vaccine to as much as $130 once the government stockpile runs out.”

Via partnerships with the National Institutes of Health and other federal agencies, vaccine makers Moderna, Pfizer and Johnson & Johnson received a total of $12 billion in taxpayer money for research, development, and procurement of vaccines against SARS-CoV-2, the virus that causes COVID-19. In all, the federal government has spent more than $30 billion, including the purchasing contracts.

Bancel defended the price hike at the hearing, telling lawmakers, “we feel we have honored the support we got and then paid it back and then some.”

“After losing money for 10 years, Moderna created a vaccine that helped end the pandemic. We were able to move quickly because of a decade of private investment in our mRNA platform and because of a decision in 2016 to build a manufacturing plant in Massachusetts,” Bancel said.

Until now, the three companies have made shots under a series of massive contracts with the US government and the governments of several other nations who sought to inoculate their entire populations against the virus. In those contracts, Moderna charged the US between $15 and $26 per vaccine dose, with full inoculation being a two-dose series. Later, the US bought several rounds of booster shots as well.

According to Bancel, the new pricing scheme of $130 per shot reflects what the company expects to be a 90% drop in sales volume later this year. In its 2022 fourth quarter earning reports last month, Moderna reported a 70% drop in profits.

When the price hike was announced in January, Sanders sent Bancel a letter urging him to lower the price. After Sanders used his power as Senate health committee chief to call on Bancel to testify last month, Moderna announced that the vaccine would remain available “at no cost” to patients regardless of insured status.

“Everyone in the United States will have access to Moderna’s COVID-19 vaccine regardless of their ability to pay,” the company said.

At the time, many assumed this was a reversal of their price hike, but at the Wednesday hearing it became clear that the February statement was in fact simply a reference to the shot being covered by health insurance plans and Moderna offering a “patient assistance program” for uninsured recipients.

'Significant Opportunity' For Profit

Indeed, as early as March 2021, as mass vaccination was just getting underway in the United States, all three companies were boasting to their investors about their plans to dramatically raise vaccine prices once the federal government contracts ended.

“As we move from a pandemic state, from a pandemic situation to an endemic situation, normal market forces, normal market conditions will start to kick in,” Pfizer Chief Financial Officer (CFO) Frank D’Amelio told investors at the Barclays Global Healthcare Conference on a March 11, 2021.

“And factors like efficacy, booster ability, clinical utility will basically become very important, and we view that as, quite frankly, a significant opportunity for our vaccine from a demand perspective, from a pricing perspective, given the clinical profile of our vaccine.”

A month prior, D’Amelio had given investors a target price of $150 to $175 per shot.

Hoge, the Moderna president, had similar words at the Barclays conference, telling investors that “post-pandemic, as we get into those what I will call seasonal epidemics that you would expect to happen with a SARS-CoV-2 virus, we would expect more normal pricing based on value.”

While the World Health Organization (WHO) defines whether or not a pandemic exists, the Biden administration has signaled that its declaration of a Public Health Emergency will be allowed to expire in May 2023.

— Fantine Gardinier | March 23, 2023

[alphst]

Moderna Inc (MRNA) Q4 2022 Earnings Call Transcript

$Moderna Inc Q4 2022 Earnings Call Transcript #earnings #markets #investing

Moderna Inc (NASDAQ:MRNA) Q4 2022 Earnings Call dated Feb. 23, 2023. Corporate Participants: Lavina Talukdar — Head of Investor Relations Stephane Bancel — Chief Executive Officer Stephen Hoge — President Arpa Garay — Chief Commercial Officer Jamey Mock — Chief Financial Officer Analysts: Salveen Richter — Goldman Sachs — Analyst Gena Wang — Barclays — Analyst Matthew Harrison — Morgan Stanley —…

[vilaspatelvlogs]

कोविड बिलियनेयर: साल भर पहले इन्हें लोग जानते तक नहीं थे, महामारी के कारण बिजनेस बढ़ा तो बन गए अरबपति

कोविड बिलियनेयर: साल भर पहले इन्हें लोग जानते तक नहीं थे, महामारी के कारण बिजनेस बढ़ा तो बन गए अरबपति

Hindi News Business Adar Poonawalla Net Worth | World’s New Billionaires 2020 List Update; Adar Poonawalla, Cyrus Poonawalla Ads से है परेशान? बिना Ads खबरों के लिए इनस्टॉल करें दैनिक भास्कर ऐप मुंबई33 मिनट पहले कॉपी लिंक बायोएनटे�� के CEO उगुर साहिन की नेटवर्थ 4.2 अरब डॉलर और मॉडर्ना के CEO स्टीफन बैंसेल की नेटवर्थ 4.1 अरब डॉलर हो गई है। फार्मा इंडस्ट्री से जुड़े कम से कम 50 लोग 2020 में…

[dermontag]

Patentschutz in 92 Ländern fällt Moderna entwickelt 15 neue Impfstoffe 08.03.2022, 12:35 Uhr Im Kampf gegen das Corona-Virus unterstützt der Pharmakonzern Moderna ärmere Länder und verzichtet auf die Durchsetzung seiner Patente. Zudem plant das Unternehmen eine große Impfstoff-Offensive. In den kommenden drei Jahren sollen unter anderem Vakzine gegen Ebola und Malaria entwickelt werden. Der US-Konzern Moderna verzichtet in 92 Ländern mit niedrigen und mittleren Einkommen dauerhaft auf den Patentschutz seines Corona-Impfstoffes. Man werde die Patente in diesen Ländern "nie" durchsetzen, heißt es vom Unternehmen. Voraussetzung sei, dass diese Impfstoffe ausschließlich zur Verwendung in diesen Ländern hergestellt werden. Es handelt sich um Länder, in denen Gavi, die internationale Impfallianz aus Regierungen, Firmen, Stiftungen und UN-Organisationen, das Covax-Programm durchführt. Moderna-Präsident Stephen Hoge sagte der "Wirtschaftswoche", das Unternehmen verzichte auch auf entsprechende Lizenzeinnahmen "Für die Nutzung der Patente verlangt Moderna kein Geld. Wir machen damit keinen Gewinn - im Gegenteil." Moderna gab außerdem bekannt, Impfstoffe gegen 15 neue oder bisher vernachlässigte Viren und Bakterien entwickeln und damit das Risiko einer erneuten Pandemie verringern zu wollen. Der Pharmakonzern will sich auf die 15 Krankheitserreger konzentrieren, die von der Weltgesundheitsorganisation (WHO) und der globalen Impf-Partnerschaft Cepi als die größten Risiken für die öffentliche Gesundheit angesehen werden. Gewappnet für eine neue Pandemie Unter anderem will Moderna bis 2025 die Entwicklung von Impfstoffen gegen das Dengue-Fieber, Ebola, Malaria und Tuberkulose vorantreiben. Es müsse nicht in jedem Fall die gesamte Forschung bis hin zur Vermarktung des Impfstoffs erfolgen, sagte Moderna-Chef Stéphane Bancel der Nachrichtenagentur AFP. Vielmehr wolle Moderna die Entwicklung der Impfstoffkandidaten bis hin zu ersten klinischen Versuchen am Menschen vorantreiben. Mehr zum Thema Es gehe darum, eine Art Impfstoff-"Bibliothek" aufzubauen, die im Falle einer erneuten Pandemie bereit stehe, sagte Bancel. Dann könnten Forscher die Impfstoff-Kandidaten weiterentwickeln und direkt mit Phase-3-Studien beginnen, der letzten Etappe vor der Markteinführung. Das Unternehmen, das einen der Impfstoffe gegen das Coronavirus auf den Markt gebracht hat, setzt eigenen Angaben zufolge bei seiner Forschung auf die Zusammenarbeit mit öffentlichen und privaten Laboren. Dazu nutze es das Programm "mRNA Access", das Forschern aus der ganzen Welt die Möglichkeit biete, die Technologieplattform für Messenger-RNA zu nutzen, um in ihren eigenen Laboren an neu auftretenden Infektionskrankheiten zu forschen.

[athibanenglish]

Pfizer CEO unsure on need for fourth dose of Covid-19 vaccine

Pfizer CEO unsure on need for fourth dose of Covid-19 vaccine

WASHINGTON: Pfizer Inc Chief Executive Officer Albert Bourla said on Monday he was unsure about the need for a fourth dose of Covid-19 vaccine and that a shot targeting the highly contagious Omicron variant would be ready in March. The comments contrasted with those made by Moderna Inc CEO Stephen Bancel, who said last week people could need another shot in the fall of 2022 as the efficacy of…

[disillusioned41]

A week after similar news from Pfizer, the American biotechnology company Moderna announced Monday that a late-stage trial shows its experimental coronavirus vaccine is 94.5% effective, provoking a fresh wave of demands that Big Pharma giants and policymakers worldwide ensure that any Covid-19 vaccine developed using taxpayer money and government support be safe, free, and available to all.

"This is a pivotal moment in the development of our Covid-19 vaccine candidate," Moderna CEO Stéphane Bancel said in a statement. "Since early January, we have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matters. This positive interim analysis from our phase 3 study has given us the first clinical validation that our vaccine can prevent Covid-19 disease, including severe disease."

An independent board appointed by the National Institutes of Health analyzed the trial results for the Moderna vaccine, which was developed in collaboration with the Vaccine Research Center, part of NIH's National Institute of Allergy and Infectious Diseases. The institute's director, Dr. Anthony Fauci, told the New York Times on Monday that "aspirationally, you would like to see 90, 95%, but I wasn't expecting it. I thought we'd be good, but 94.5% is very impressive."

Moderna plans to apply for emergency use authorization with the U.S. Food and Drug Administration (FDA) "in the coming weeks" and hopes to have 20 million doses ready by the end of the year, then manufacture 500 to one billion doses in 2021. Like the vaccine developed by the American pharmaceutical company Pfizer and German drugmaker BioNTech—which a phase 3 study found may be more than 90% effective—each person requires two doses.

Campaigners pointed out on Monday that many of Moderna's doses have already been claimed by wealthy countries. According to the London-based group Global Justice Now, 780 million doses have been sold to rich governments, or 78% of the billion doses the company says it can produce by the end up next year.

"We welcome any good news when it comes to a coronavirus breakthrough, but sadly most of the world cannot celebrate today," said Nick Dearden, director of Global Justice Now. "Moderna's is predicted to be the most expensive potential vaccine on the market, at around $35 a dose, even though it has been made with vast public support. The U.S. government has spent over $1 billion in direct support alone. What's more, well over 78% of what Moderna is likely to produce has already been sold to very wealthy countries."

"At the end of the day these vaccines are a big part of our route out of this crisis," Dearden added. "We appreciate that Moderna has said it won't enforce patents as long the pandemic continues, but this alone is not sufficient to ensure this vaccine benefits humanity. This is truly a taxpayer funded vaccine and should be placed in the public sphere through the World Health Organization so the whole world can benefit."

Amnesty International detailed in a statement that the United States has paid for 100 million doses from Moderna, with an option of 500 million more, while Canada has ordered 56 million, Japan has ordered 50 million, and the European Commission completed talks with the company for up to 160 million.

"Having already sold most of its potential 2021 vaccine supply to rich countries, Moderna must follow through on its promise to allow others to make the vaccine, and provide the knowledge and technology to do so, once the vaccine has proven to be safe and effective," declared Stephen Cockburn, head of Amnesty's Economic and Social Justice Program.

Noting last week's announcement, Cockburn argued that "companies like Moderna and Pfizer-BioNTech have a responsibility to respect human rights, and they should play a leading role towards a global solution to Covid-19 by sharing and ensuring affordable prices. They must not act in a way that allows governments to hoard vaccines for a privileged few."

"We can only put an end to Covid-19 if companies ensure that those most in need of life-saving vaccines are not left behind. It's time for companies to live up to their human rights responsibilities and ensure the widest possible access to their innovations," he added, echoing a warning last week from United Nations human rights experts.

As Peter Maybarduk, director of Public Citizen's Access to Medicines program, put it Monday: "This is the people's vaccine. The NIH's vaccine. It is not merely Moderna's vaccine. Federal scientists helped invent it and taxpayers are funding its development. We all have played a role. It should belong to humanity."

Maybarduk directed his message to both outgoing President Donald Trump—who has yet to publicly accept the results of the November 3 election—and President-elect Joe Biden, who said earlier this month that "I want everyone to know on day one, we're going to put our plan to control this virus into action."

According to Maybarduk, "Both the current administration and President-elect Biden have the opportunity to make this vaccine a public good that is free and available to all and help scale up global manufacturing, in order to prevent medical rationing that could become a form of global vaccine apartheid."

"If the NIH vaccine proves safe and effective, it could be one of the most important medical tools of our time. But limited supply could keep this vaccine out of reach for billions of people worldwide, extending their suffering for several years," he warned.

In a separate statement Monday about a new Public Citizen report, Maybarduk delivered a similar message to the global community, saying that "in the worst health crisis in a century, vaccine funders must use every tool at their disposal to share technology and teach the world to make vaccines."

The report, authored by Public Citizen law & policy researcher Zain Rizvi, focuses on the Coalition for Epidemic Preparedness Innovations (CEPI), which is made up of foundations and governments and co-leads the WHO's Covid-19 vaccine access facility, known as COVAX. The report says in part:

No one corporation can supply the world with a vaccine. CEPI—and COVAX—should make all their contracts publicly available, and enforce corporate compliance with their equitable access conditions. They should also leverage the full extent of their existing authority to increase technology transfer and scale-up affordable supply. Moving forward, they should coordinate with the WHO's sister initiative, the Covid-19 technology access pool, to openly share technology, so that all qualified manufacturers are able to scale-up access.

"CEPI and COVAX should live up to their stated commitments to transparency," Rizvi said Monday. "Accountability begins with transparency."

As of Monday afternoon, there were more than 54.6 million Covid-19 cases and 1.32 million deaths worldwide. The United States continues to lead both counts, with over 11 million infections and 246,500 deaths. With surges occurring nationwide, some state leaders are imposing or reimposing restrictions.

[alphst]

Moderna Inc (MRNA) Q3 2022 Earnings Call Transcript

$Moderna Inc Q3 2022 Earnings Call Transcript #earnings #markets #investing

Moderna Inc (NASDAQ:MRNA) Q3 2022 Earnings Call dated Nov. 03, 2022. Corporate Participants: Lavina Talukdar — Head of Investor Relations Stephane Bancel — Chief Executive Officer Stephen Hoge — President Arpa Garay — Chief Commercial Officer Jamey Mock — Chief Financial Officer Analysts: Salveen Richter — Goldman Sachs — Analyst Matthew Harrison — Morgan Stanley — Analyst Edward Tenthoff — Piper…

[xtruss]

Coronavirus: Moderna Covid Vaccine Candidate Almost 95% Effective, Trials Show

Analysis | What Does the Moderna Vaccine Mean?

US-based biotech firm is latest to reveal impressive results from phase 3 trials of jab

— By Ian Sample Science editor | The Guardian USA | Monday November 16, 2020

The race for a coronavirus vaccine has received another shot in the arm with the US biotech firm Moderna becoming the latest to reveal impressive results from phase 3 trials of its jab.

An interim analysis released on Monday, and based on the first 95 patients with confirmed Covid infections, found the candidate vaccine has an efficacy of 94.5%. The company said it planned to apply to the US regulator, the Food and Drug Administration, for emergency-use authorisation in the coming weeks. In the analysis, 90 of the patients had received the placebo with the remaining five the vaccine.

The results are the latest encouraging news to emerge from the breakneck effort to develop a vaccine against coronavirus and follow a similar interim analysis earlier this month from a collaboration between Pfizer and the German firm BioNTech, which suggest its vaccine is 90% effective at preventing illness.

The Moderna vaccine, which is being trialled in more than 30,000 volunteers, is not expected to be available outside the US until next year. The biotech company said it would have 20m doses ready to ship in the US before the end of 2020 and hoped to manufacture 500m to 1bn doses globally next year.

So far, the UK does not stand to benefit from the vaccine but a government spokesman confirmed it was in “advanced discussions” to procure it. The CEO of Moderna, Stéphane Bancel, said that with approval, doses could be available in Europe, including the UK, “as early as January.”

Moderna has agreed to provide the US with 100m doses, with an option to buy 400m more. Japan, Canada, Switzerland, Qatar and Israel have also signed agreements, and the European commission has a “potential purchase agreement” for 80m-160m doses. The UK chose not to participate in the EU vaccine purchase scheme, with the health secretary, Matt Hancock, arguing in July that the government could source a vaccine faster on its own.

The Moderna vaccine, which is based on similar mRNA technology as BioNTech’s, is expected to be assessed by the FDA on a final analysis of 151 Covid cases among trial participants who will be followed on average for more than two months.

If the results remain as impressive as the trial goes on, the Moderna vaccine could potentially provide a major advantage over the Pfizer vaccine. While Pfizer’s vaccine requires ultracold freezing between -70C and -80C from production facility to patient, Moderna said it had improved the shelf life and stability of its own vaccine, meaning that it can be stored at standard refrigeration temperatures of 2C to 8C for 30 days. It can be stored for six months at -20C for shipping and long-term storage, the company said.

At £38 to £45 for a course of two shots, Moderna’s vaccine is more expensive than the other frontrunners. AstraZeneca and Oxford University are aiming to sell their vaccine at about £3 a dose, while vaccines in trial with Johnson and Johnson and a collaboration between Sanofi and GSK are both expected to cost about £8 a dose. Pfizer is charging the US about £30 for a two-shot course. The UK has ordered 40m Pfizer shots but none of the Moderna vaccine.

Moderna’s two-shot vaccine injects genetic material called mRNA into the body, which cells then use to churn out the spike protein the virus uses to invade cells. The spike protein covers the surface of the virus and is one of the main targets of the body’s immune response to wipe out the infection.

The interim results are based on an analysis of confirmed Covid cases among both placebo and vaccinated arms of the trial, starting two weeks after the second dose is administered.

Given the relatively small number of cases analysed there is some statistical uncertainty over the 94.5% figure. But Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine, said that based on the numbers released, the efficacy was still likely to be better than 85%.

A question mark that remains over the Pfizer vaccine is whether it prevents serious illness. The Moderna results, released by an independent data safety monitoring board, are encouraging on this point. Of 11 participants who developed severe Covid while on the trial, all were in the placebo group. The results also suggest the vaccine is effective in older people and those from diverse ethnic backgrounds.

Moderna’s interim analysis includes a safety review of data available so far. The company said it had found no significant safety concerns, with most reactions being mild to moderate and short-lived. Among the side effects reported were injection site pain in 2.7% of trial volunteers after the first jab. After the second, the most significant side effects included fatigue in 9.7%, muscle pain in 9% and joint pain in 5%. Others had headaches, other pains, or redness at the injection site.

Prof Trudie Lang, professor of global health research at the University of Oxford, said: “It is very good news indeed to see another vaccine coming through with similar efficacy results as were reported last week from Pfizer.

“This is also an interim analysis, which means that there were enough cases within the vaccinated volunteers to give statistical significance and allow the team to break the blind to determine who had the active vaccine and who had placebo.

“This is really encouraging and it further demonstrates that a vaccine for Covid is a real probability and that having more than one supplier should help assure better and more equitable global availability.”

Peter Openshaw, professor of experimental medicine at Imperial College, London, said the Moderna results were “tremendously exciting” and boosted optimism that a choice of good Covid vaccines would be available in the next few months.

He said the inclusion of high-risk and elderly people in the Moderna trial suggested the vaccine would protect those most vulnerable to the disease, while the reported side effects were “what we would expect with a vaccine that is working and inducing a good immune response”.

“Moderna have also announced that the vaccine can be kept in a conventional freezer at -20C for up to 6 months, and that once thawed the vaccine can be kept for up to 30 days at standard refrigerator temperatures of 2 to 8C. This makes the vaccine much easier to deliver,” he said.

“This announcement adds to the general feeling of optimism about vaccines for Covid-19. What we still don’t know is how long any protective immunity may last. For that, we will need to wait,” he added.

Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, which co-developed the vaccine said the Moderna jab and others still in trials were “the light at the end of the tunnel.” But he urged people to continue to observe the guidelines to reduce the spread of the disease. “We should not let the accomplishment of an effective vaccine have us feel we can let our guard down,” he said. “In fact, it should be an incentive to double down as we then ultimately have the synergy between a vaccine and a public health measure which will get us out of the very difficult situation.”

[listinsemanal]

Informe de Moderna indica que los resultados definitivos de su vacuna para el COVID-19 estarían listos en 2021 | Salud | La Revista

Informe de Moderna indica que los resultados definitivos de su vacuna para el COVID-19 estarían listos en 2021 | Salud | La Revista

Nueva York –

El consejero delegado de la farmacéutica Moderna, Stephen Bancel, dijo el jueves que podrían conocer si su vacuna contra el COVID-19 es eficaz en octubre, aunque consideró que lo más probable es que esos esperados datos sobre la fase final de su desarrollo lleguen en noviembre.

Las declaraciones de Bancel fueron hechas al canal CNBC después de que Modernapresentara su esperado…

[thisdaynews]

US drugmaker reports progress on COVID-19 vaccine trial

New Post has been published on https://thebiafrastar.com/us-drugmaker-reports-progress-on-covid-19-vaccine-trial/

US drugmaker reports progress on COVID-19 vaccine trial

US biotech firm Moderna reported promising early results on Monday from the first clinical tests of an experimental vaccine against the novel coronavirus performed on a small number of volunteers.

(adsbygoogle = window.adsbygoogle || []).push();

The Cambridge, Massachusetts-based company said the vaccine candidate, mRNA-1273, appeared to produce an immune response in eight people who received it similar to that seen in people convalescing from the virus.

“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection,” said Moderna’s chief medical officer Tal Zaks.

(adsbygoogle = window.adsbygoogle || []).push();

“These data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials,” Zaks said.

President Donald Trump welcomed the news saying “it’s incredible what they can do and I’ve seen results.”

“And the results are staggeringly good,” Trump told reporters. “So I’m very happy and the market’s up very big.”

(adsbygoogle = window.adsbygoogle || []).push();

Wall Street stocks posted substantial gains on Monday with the Dow Jones Industrial Average adding 3.85 percent and the S&P 500 up 3.15 percent.

Moderna shares gained 19.96 percent to close at $80.00 in New York.

Moderna, which was founded nine years ago, said the vaccine “was generally safe and well-tolerated” and that patients suffered no more than redness or soreness from the shots.

(adsbygoogle = window.adsbygoogle || []).push();

In a conference call, Moderna chief executive Stephane Bancel said the preliminary tests inspired confidence that mRNA-1273 has “a high probability to provide protection” against the virus.

“We could not be happier about these interim data,” Bancel said of the Phase 1 test, the first of three in the development of a vaccine.

Separate tests performed on mice showed that the vaccine prevented the virus from replicating in their lungs, according to the company.

(adsbygoogle = window.adsbygoogle || []).push();

The US government has invested nearly half a billion dollars in the development of Moderna’s vaccine candidate.

It is being developed in a partnership with the National Institute of Allergy and Infectious Disease headed by Anthony Fauci and the clinical test was carried out by the National Institutes of Health.

Three groups of 15 patients aged 18 to 55 received three different doses of the vaccine in the Phase 1 test, the complete results of which are not yet known.

(adsbygoogle = window.adsbygoogle || []).push();

The Phase 2 trial, with 600 subjects, has already received the green light from the US Food and Drug Administration and Moderna said they should begin this quarter.

A Phase 3 trial, the largest and most important to validate the efficacy of a vaccine, should begin in July.

“The Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase 3 study in July,” said Bancel, Moderna’s CEO.

(adsbygoogle = window.adsbygoogle || []).push();

Based on Phase 1 partial results, Moderna said they would no longer study the highest dose since the lower doses appeared to provide some effect.

“The lower the dose, the more people we expect to be able to protect,” said Moderna president Stephen Hoge.

Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, said that while it was difficult to be sure of the results “from a press release,” there was reason for optimism.

(adsbygoogle = window.adsbygoogle || []).push();

“It must be noted that this is a Phase 1 study which has an object of showing the vaccine is able to induce an antibody response and that the dose range is appropriate,” Evans said.

“It will not be until the Phase 3 trial is completed that it will be known whether the vaccine actually prevents COVID-19 disease,” he added.

Trump has said he wants 300 million vaccine doses by January 2021 to protect the US population and his administration has provided funding to Moderna, Johnson & Johnson, and France’s Sanofi.

(adsbygoogle = window.adsbygoogle || []).push();

The development of a vaccine usually takes years but the coronavirus pandemic, which has caused more than 315,000 deaths, has given unprecedented urgency to the search.

A dozen clinical trials are taking place around the world, half of them in China, according to the London School of Hygiene & Tropical Medicine.

China has said that it is carrying out tests on humans of five experimental vaccines.

(adsbygoogle = window.adsbygoogle || []).push();

The challenge is not only finding a safe and efficient vaccine but also producing billions of doses.

Several large laboratories, including Moderna, have said they would immediately begin production of an eventual vaccine even before the completion of all of the clinical trials.

Moderna recently announced a partnership with the giant drugmaker Lonza to boost its manufacturing capacity to up to one billion doses a year.

[jobsearchtips02]

Specialists provide most likely COVID-19 vaccine timeline: not prior to election

President Trump has suggested that a coronavirus vaccine might become available “right around” the election on November 3.

But public-health experts, monetary experts, and US government authorities have actually said that timeline is unrealistic.

Most professionals think there’s little hope of a vaccine being prepared before completion of the year.

Under the most positive situation, drug companies like Pfizer and Moderna could launch favorable results from their human trials in October.

Go to Business Expert’s homepage for more stories

The answer to among the biggest concerns of the year– when a coronavirus vaccine be prepared?– differs depending upon who you ask.

Last month, the Centers for Illness Control and Avoidance informed public-health authorities in every state to prepare for vaccine circulation by November 1. Robert Redfield, director of the CDC, stated the objective was to get ahead of the game, considering that the agency anticipates one or more vaccines to be ready by November or December.

President Donald Trump has actually also recommended that a vaccine might appear “right around” the election on November 3.

” We stay on track to deliver a vaccine before the end of the year and perhaps even prior to November 1,” Trump said during a White Home news conference on Friday. “We think we can most likely have it sometime throughout the month of October.”

However public-health experts state there’s little hope of a vaccine being ready prior to completion of the year, let alone before the election.

On Tuesday, the CEOs of 9 pharmaceutical business issued a rare joint promise assuring to put safety prior to speed when developing a vaccine. The companies vowed to just apply for emergency FDA approval after showing that their vaccines were safe and reliable through a phase 3 trial– a vaccine’s last test before it can be dispersed to the public.

Under the most positive situation, drug companies could release positive results from phase 3 trials in October. Pfizer and Moderna have each said that’s a possibility.

But when it pertains to presenting that vaccine, many experts concur that it won’t occur till2021 Here’s the most likely timeline according to federal government officials, public-health specialists, and Wall Street analysts.

What government authorities prepare for: a commonly available vaccine in mid-2021

The United States is lining up an army of vaccine candidates Through Operation Warp Speed, the government is moneying the manufacturing of 6 promising candidates in large amounts while scientific trials are still continuous. The program wishes to provide 300 million doses of a safe, reliable vaccine by January 2021.

Up until now, 3 drug business in that program– AstraZeneca, Moderna, and Pfizer– have displayed in early data that their vaccines produced immune responses without causing severe negative effects. AstraZeneca just paused its phase 3 trial due to a potential unfavorable response in a UK individual.

Moderna and Pfizer’s stage 3 trials both started in July and are slated to include 30,000 volunteers. As of last week, Pfizer said it had registered 23,000 individuals, while Moderna had actually enrolled more than 21,000

Moncef Slaoui, the chief adviser to Operation Terminal velocity, informed NPR last week that it was “very unlikely however not impossible” for those trials to end up by the end of October. A more reasonable estimate, he said, is that a vaccine would become available for high-risk populations, including healthcare workers and individuals 70 years or older, by the end of2020 By that time, the US could have enough capability to inoculate in between 20 and 25 million individuals, he included.

Dr. Barney Graham, Deputy Director at the Vaccine Research Center at the National Institutes of Health, consults with President Donald Trump throughout a lab trip on March 3, 2020, in Bethesda, Maryland.

Evan Vucci/Associated Press.

The vaccine could then end up being widely readily available to Americans by the 2nd quarter of 2021, Slaoui formerly informed Business Insider By then, he added, the US might have currently immunized around 70 or 80 million individuals.

That’s similar to the timeline put forward by Anthony Fauci, director of the National Institute of Allergic Reaction and Contagious Diseases.

On Tuesday, Fauci said professionals will most likely know if a vaccine is safe and efficient by the end of 2020.

Fauci included that it’s “unlikely” a vaccine would be ready before the election.

” To attempt to forecast whether it takes place on a particular week before or after a specific date in early November is well beyond anything that any scientist might tell you and be confident that they understand what they’re stating,” Collins stated.

What public-health specialists think: It’s unrealistic to anticipate outcomes this fall

Before a vaccine can be distributed to the public, the Fda must release an emergency situation usage permission (EUA). EUAs require less strict evaluation than a full-fledged FDA approval.

FDA commissioner Stephen Hahn told the Financial Times last month that his agency would think about issuing an EUA for a vaccine prior to human trials are total if a trial revealed enough positive data to prove that the benefits of authorizing the vaccine exceeded the risks.

” If a vaccine is extremely efficient– let’s state, more than 90%reliable– it is possible that we would learn prior to all 30,000 people are registered in the trial,” Luciana Borio, the previous acting chief scientist at the FDA, just recently wrote on Twitter

Scientists are hoping for a vaccine that’s at least 75?ficient, he included, though US regulators have stated they’ll authorize a vaccine that’s 50?ficient.

Scientist Xinhua Yan works in the Moderna lab in Cambridge, Massachusetts, on February 28,2020

David L. Ryan/The Boston Globe/Getty Images.

” Early fall is unrealistic,” Ashish Jha, dean of Brown’s School of Public Health, told MSNBC in July. “We simply require the time to follow people to make certain they’re not having adverse responses.”

Complicating the timeline further is the fact that both the Moderna and Pfizer vaccines need individuals to get two shots

Dr. Paul Offit, director of the Vaccine Education Center at Children’s Health center of Philadelphia, informed WebMD it would be “exceptional” if volunteers got their second dosage in September. And after that, he stated, they ‘d have to wait another two weeks to see if they developed an immune action.

” I can’t imagine we would have data on this by any earlier than early next year,” Offit stated.

Jha, likewise, told Organization Expert that researchers need to have “a lot more information” about a vaccine in January. He prepares for that a candidate might be all set to distribute in early 2021.

Dr. Naor Bar-Zeev, an associate professor at the Johns Hopkins Bloomberg School of Public Health, used a less optimistic timeline to CBS Baltimore: He thinks a vaccine most likely won’t be commonly available till the end of 2021.

Last week, Pfizer CEO Albert Bourla stated he anticipates to understand whether the company’s vaccine works by the end of October.

Getting outcomes in October would be a “best-case scenario” for Moderna, the company’s CEO, Stephane Bancel, recently informed Company Expert

In a research note to financiers, analysts at Morgan Stanley forecasted that both Moderna and Pfizer would produce trial results by mid-November

Experts at Jefferies Financial Group, however, estimated that Moderna’s vaccine wouldn’t get emergency situation approval till early 2021.

Even a commonly offered vaccine will not bring an instant return to regular.

” I am pretty confident that we’re not going to have a kind of vaccine that will in some way immediately get rid of the pandemic,” Jha said.

Andrew Dunn contributed reporting.

Filling Something is filling.

%%.

from Job Search Tips https://jobsearchtips.net/specialists-provide-most-likely-covid-19-vaccine-timeline-not-prior-to-election/

[cryptonewstrending]

Moderna (MRNA) Stock Rises 2.59%, mRNA-1273 Vaccine Will Be Ready for Distribution in 2021

Coinspeaker Moderna (MRNA) Stock Rises 2.59%, mRNA-1273 Vaccine Will Be Ready for Distribution in 2021 Massachusetts-based Moderna Inc (NASDAQ: MRNA), one of the COVID-19 vaccine race front-runners, is now getting ready to launch a Phase 3 trial of its mRNA-1273 vaccine in July. According to Moderna CEO Stephen Bancel, the company stands a good chance of reaching the vaccine distribution in 2021. Bancel stated: “It seems to be possible that we could have efficacy data by, let’s say, Thanksgiving.” Moderna has made enormous progress in developing its COVID-19 vaccine. Its…

The post Moderna (MRNA) Stock Rises 2.59%, mRNA-1273 Vaccine Will Be Ready for Distribution in 2021 appeared first on CryptoNewsTrending.

source https://cryptonewstrending.com/moderna-mrna-stock-rises-2-59-mrna-1273-vaccine-will-be-ready-for-distribution-in-2021/

[vishnuvvvvvvi]

Stephen Bancel, the CEO of Moderna Therapeutics, believes the company's coronavirus vaccine has an 80% to 90% chance of being approved by the US Food and Drug Administration.

[itsfinancethings]

Another early investor of Moderna is on the cusp of owning a stake worth at least $1 billion after the biotech firm reported encouraging early trial results for an experimental Covid-19 vaccine.

The value of board member Bob Langer’s 3.2% holding, including stock options, rose to $934.3 million Monday, as the shares surged 20% to a record $80 each. Langer, a professor at the Massachusetts Institute of Technology, would be at least the third individual with Moderna holdings topping $1 billion, joining Chief Executive Officer Stephane Bancel and Harvard University professor Timothy Springer.

Moderna, whose shares have more than quadrupled this year, released interim data from a small phase 1 trial showing positive early signs that the vaccine can create an immune system response to the virus in humans. The news helped fuel a broader surge in stocks, with the S&P 500 Index advancing 3.2%, the most since April 8.

The company priced a stock offering to fund manufacturing of its coronavirus vaccine at $76 a share, 5% below the last close, people familiar with the deal said after Monday’s market trading.

Langer, 71, has licensed or sub-licensed patents to more than 400 biotech, pharmaceutical, chemical and medical companies, according to his biography at MIT’s Langer Lab.

Bancel and Springer own stakes worth $2.45 billion and $1.38 billion, respectively, according to the Bloomberg Billionaires Index. The biggest beneficiary of the stock surge is top shareholder Flagship Pioneering Inc., a firm started by Moderna co-founder Noubar Afeyan. Flagship distributed 10 million shares to investors last week, leaving it with an 11% stake worth $3.27 billion. Afeyan declined to elaborate when asked about how much of the stock he owns individually.

“The broader market reaction is a measure of the need people have to perceive that there’s a scientific, technological solution to this kind of battle,” Afeyan said in a phone interview. “We’ve increased expectations, but that hasn’t changed what we do.”

‘Warp Speed’

Bancel and other Moderna executives, including outgoing Chief Financial Officer Lorence Kim and President Stephen Hoge, have been selling shares, some through prearranged trading plans. Bancel has sold about 200,000 shares since Feb. 21, data compiled by Bloomberg show.

Moncef Slaoui, who owned 82,508 shares as of Feb. 21, stepped down from Moderna’s board last week and plans to divest his stake to help lead “Operation Warp Speed,” a Trump administration effort involving the private and public sectors to accelerate the development of a vaccine, the company said in an emailed statement.

Slaoui intends to donate the incremental value accrued from his Moderna stake since the May 14 close to cancer research, Caitlin Oakley, a spokeswoman for the U.S. Department of Health & Human Services, wrote in an email.

Moderna Insiders Get Fresh Chance to Cash Out After 200% Surge

Other major shareholders include AstraZeneca Plc and Theleme Partners, the hedge fund of Patrick Degorce, a former partner of the Children’s Investment Fund.

(Updates to add stock pricing in fourth paragraph, HHS comment in second-to-last paragraph)

–With assistance from Cristin Flanagan and Emma Court.